Kabra Drugs Ltd

Kabra Drugs Ltd recorded a modest weekly gain of 1.06% closing at Rs.23.88 on 19 June 2026, underperforming the broader Sensex which rose 2.35% over the same period. The week was marked by a sharp initial rally followed by a steady decline, influenced by significant technical developments including an upgrade to a Hold rating and the formation of a bearish Death Cross. These events shaped investor sentiment and price action throughout the week.

The next results date for Kabra Drugs Ltd is 29 May 2026.

Kabra Drugs Ltd will announce its results on 13 February 2026.

Kabra Drugs has consistently generated no significant revenue from March 2021 to March 2025, with increasing operating losses reaching -1.08 Cr by March 2025, despite an improvement in shareholder's funds to 24.65 Cr due to increased equity capital. Total liabilities rose to 25.23 Cr, while financing activities resulted in a net cash inflow of 18.00 Cr.

Kabra Drugs has consistently generated no significant revenue since March 2021, with increasing operating losses and rising expenditures, particularly in employee costs. Despite a notable increase in equity capital to 23.71 Cr by March 2025, total liabilities also rose to 25.23 Cr, although the company reported a positive cash inflow of 18.00 Cr during the same period.

The next results date for Kabra Drugs is 13 November 2025.

Kabra Drugs has consistently reported zero net sales from March 2021 to March 2025, with significant operating losses reaching -1.08 Cr in March 2025, despite an increase in equity capital to 23.71 Cr and a positive cash balance of 21.00 Cr due to financing activities. Expenditures have risen sharply, primarily due to employee costs.

Kabra Drugs Ltd is experiencing notable buying activity, with the stock outperforming the Sensex recently. It has shown consecutive gains over the last two days and a significant increase over the past five years. The stock's current price is above several moving averages, indicating a positive short-term trend.

Kabra Drugs Ltd is experiencing notable buying activity, with the stock rising after two days of decline. Despite mixed short-term performance, it has shown substantial long-term growth. Today's trading indicates strong buyer interest, suggesting a potential shift in market sentiment within the pharmaceuticals and biotechnology sector.

Kabra Drugs Ltd is experiencing notable selling pressure, with consecutive losses impacting its stock performance. Over the past week and month, the stock has declined significantly, contrasting with the broader market. Despite a strong annual performance, recent trends indicate a potential shift in investor confidence.

Kabra Drugs Ltd is experiencing notable buying activity, with the stock rebounding after two days of decline. It has shown a weekly increase while outperforming the Sensex. Despite a monthly decline, the stock has demonstrated substantial long-term growth, reflecting strong investor sentiment in the pharmaceuticals sector.

Kabra Drugs' latest results indicate a flat performance in net sales at Rs 7.15 crore, but a significant decline in standalone net profit to Rs -0.50 crore, suggesting challenges in maintaining profitability. Stakeholders should monitor future developments for insights into the company's performance.